Correlation Between AstraZeneca PLC and Bristol-Myers Squibb

Can any of the company-specific risk be diversified away by investing in both AstraZeneca PLC and Bristol-Myers Squibb at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining AstraZeneca PLC and Bristol-Myers Squibb into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between AstraZeneca PLC ADR and Bristol Myers Squibb, you can compare the effects of market volatilities on AstraZeneca PLC and Bristol-Myers Squibb and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in AstraZeneca PLC with a short position of Bristol-Myers Squibb. Check out your portfolio center. Please also check ongoing floating volatility patterns of AstraZeneca PLC and Bristol-Myers Squibb.

Diversification Opportunities for AstraZeneca PLC and Bristol-Myers Squibb

0.46

Correlation Coefficient

AstraZeneca PLC  Bristol-Myers Squibb

Very weak diversification

The 3 months correlation between AstraZeneca and Bristol-Myers is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding AstraZeneca PLC ADR and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and AstraZeneca PLC is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on AstraZeneca PLC ADR are associated (or correlated) with Bristol-Myers Squibb. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of AstraZeneca PLC i.e., AstraZeneca PLC and Bristol-Myers Squibb go up and down completely randomly.

Pair Corralation between AstraZeneca PLC and Bristol-Myers Squibb

Considering the 90-day investment horizon AstraZeneca PLC ADR is expected to generate 0.35 times more return on investment than Bristol-Myers Squibb. However, AstraZeneca PLC ADR is 2.82 times less risky than Bristol-Myers Squibb. It trades about 0.48 of its potential returns per unit of risk. Bristol Myers Squibb is currently generating about -0.13 per unit of risk. If you would invest  6,889  in AstraZeneca PLC ADR on December 5, 2024 and sell it today you would earn a total of  836.00  from holding AstraZeneca PLC ADR or generate 12.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	85.71%
Values	Daily Returns

AstraZeneca PLC ADR  vs.  Bristol Myers Squibb

AstraZeneca PLC ADR

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in AstraZeneca PLC ADR are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, AstraZeneca PLC displayed solid returns over the last few months and may actually be approaching a breakup point.

Bristol Myers Squibb

Risk-Adjusted Performance

Very Weak

Over the last 90 days Bristol Myers Squibb has generated negative risk-adjusted returns adding no value to investors with long positions. Even with fragile performance in the last few months, the Stock's primary indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with AstraZeneca PLC and Bristol-Myers Squibb

The main advantage of trading using opposite AstraZeneca PLC and Bristol-Myers Squibb positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if AstraZeneca PLC position performs unexpectedly, Bristol-Myers Squibb can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will offset losses from the drop in Bristol-Myers Squibb's long position.

The idea behind AstraZeneca PLC ADR and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.